Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

ABSTRACT:

Background

The administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how this approach affected the continued clinical course of these patients.

Methods

Ten patients from a phase I clinical trial who had received MIC infusions prior to kidney transplantation were retrospectively compared to 15 matched standard-risk recipients. Follow-up was until year five after surgery.

Results

The 10 MIC patients had an excellent clinical course with stable kidney graft function, no donor-specific human leukocyte antigen antibodies (DSA) or acute rejections, and no opportunistic infections. In comparison, a retrospectively matched c

SUBMITTER: Schaier M 

PROVIDER: S-EPMC10361653 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature